Trials / Unknown
UnknownNCT05821192
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
A Prospective Clinical Study of Chemotherapy Plus Programmed Death-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-cell Lymphoma.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Ou Bai, MD/PHD · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A multi-center, prospective clinical study to evaluate the efficacy and safety of R-GDP plus PD-1 monoclonal antibody in the treatment of refractory or relapsed peripheral T cell lymphoma not otherwise specified and Angioimmunoblastic T-cell lymphoma, which has previously shown promising efficacy.
Detailed description
Objective to evaluate the efficacy and safety of R-GDP (Rituximab, Gemcitabine, Dexamethasone, Cisplatin) plus PD-1 monoclonal antibody in patients with refractory or relapsed peripheral T cell lymphoma not otherwise specified or Angioimmunoblastic T-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | 375mg/m2 by IV infusion once every 3 weeks |
| DRUG | Gemcitabine | 1 g/m2 on Days 1 by IV infusion once every 3 weeks |
| DRUG | Dexamethasone | 40 mg on Days 1 to 4 of each 3-week cycle by IV infusion |
| DRUG | Cisplatin | 75 mg/m2 on Days 1 by IV infusion once every 3 weeks |
| DRUG | PD-1 monoclonal antibody | 200mg on Days 2 by IV infusion once every 3 weeks |
Timeline
- Start date
- 2023-03-23
- Primary completion
- 2023-04-18
- Completion
- 2024-12-31
- First posted
- 2023-04-20
- Last updated
- 2023-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05821192. Inclusion in this directory is not an endorsement.